Jan, 22 2019 17:54 JST

Source: Eisai

Eisai Listed as a Global 100 Most Sustainable Corporation for the Fourth Time

Highest Ranked Japanese Company

TOKYO, Jan, 22 2019 - (JCN Newswire) - Eisai Co., Ltd. has been listed in the 2019 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. This marks Eisai's fourth inclusion on the list. Ranked 73rd, Eisai was the highest ranking Japanese company among the eight Japanese companies listed in the Global 100.

The Global 100 evaluates the sustainability of approximately 7,500 of the world's major corporations based on various corporate initiatives in areas such as ESG (environment, society and governance). Since 2005, those companies ranking among the top 100 in the world have been announced each year at the World Economic Forum in Davos. The Global 100 is based on up to 21 key performance indicators covering financial management, clean revenue, supplier performance, employee management and resource management, with the evaluations carried out based on data publicly disclosed in financial filings, integrated reports, or through other such channels.

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Based on this corporate philosophy, Eisai is striving to sustainably enhance corporate value by strengthening its ESG initiatives and increasing non-financial value.


About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

Furthermore, we invest and participate in several partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech, HealthCare

Copyright ©2019 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


"Science Based Targets (SBT) Initiative" Approves Eisai's Greenhouse Gas Reduction Targets
May 17 2019 15:34 JST
 
Eisai to Present Data on Oncology Pipeline and Products at 55th Asco Annual Meeting
May 16 2019 07:37 JST
 
Eisai Enters Into Licensing Agreement With Medac Concerning Anti-Rheumatic Agent Methotrexate Subcutaneous Injection in Japan
May 10 2019 12:34 JST
 
Eisai: Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401
May 10 2019 11:55 JST
 
Eisai and Allm Enter Into Capital and Business Alliance Agreement for ICT Healthcare Solutions
May 09 2019 11:33 JST
 
Eisai Commences Venture Investment Business Aimed at Accelerating Innovation in Drug Creation and Establishment of Ecosystem Platform
May 09 2019 11:06 JST
 
Eisai and UK Dementia Research Institute Jointly Launch New Post-Doctoral Programme to Accelerate Dementia Research
May 08 2019 08:37 JST
 
Eisai Buys Out Purdue Rights to End Collaboration
May 01 2019 08:09 JST
 
Eisai to Present Latest Data on Lemborexant and Perampanel at Annual American Academy of Neurology Meeting
April 24 2019 16:53 JST
 
Eisai Selected as Competitive ICT Strategy Company for 2019
April 24 2019 08:36 JST
 
More Press release >>

Latest Press Release


More Latest Release >>